Drugs
Researchers from Northeastern University have made significant advancements in overcoming multidrug resistance in cancer cells using a combination of gene silencing and nanoparticle-mediated delivery of paclitaxel. The study, published in Cancer Chemotherapy and Pharmacology in 2009, demonstrates the efficacy of this approach in treating refractory tumors. By silencing the MDR-1
Drugs
Researchers from the University of Mississippi have identified a potential new therapeutic approach for breast cancer treatment by investigating the effects of a natural compound, epoxypseudoisoeugenol-2-methyl butyrate (EPB), on the activation of NF-kappa B, a protein complex involved in cancer development and resistance to treatment. The study, published in Cancer
Drugs
Clinical trials involving seliciclib, a cyclin-dependent kinase (CDK) inhibitor, have shown promise in treating nasopharyngeal carcinoma, a type of cancer that affects the upper respiratory tract. Researchers at the National University in Singapore conducted a study to evaluate the pharmacodynamic effects of seliciclib in patients with nasopharyngeal carcinoma. The results
Drugs
In a groundbreaking study, researchers at the University of Edinburgh have discovered a novel approach to target small cell lung cancer cells using the anti-cancer agent [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (SP-G). This compound modulates gastrin releasing peptide (GRP) and arginine vasopressin signaling,
Drugs
Researchers at the University of Bologna in Italy have made a breakthrough in understanding the genetic factors contributing to variability in antidepressant response. By examining a panel of markers in the 5-HT1A gene, they identified three variants - rs10042486C/T, rs1364043T/G, and a combination of rs10042486-rs6295-rs1364043 - that are
Drugs
The 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc) took place in San Diego, CA, on October 30, 2008. The meeting covered various topics in tumor immunology and immunotherapy, including cytokines in cancer immunology, anti-angiogenic therapy, and immune monitoring of cancer immunotherapy. The event was
Drugs
Researchers at the University of California have developed a biodegradable nanoprobe that enables noninvasive imaging of angiogenesis, a critical process involved in tumor growth and metastasis. The nanoprobe, designed to target alpha(v)beta(3) integrin receptors, has a modular multivalent core-shell architecture that imparts biological stealth and dictates pharmacokinetics.
Drugs
Scientists at East Carolina University investigated the vascular activity of scutellarin, a flavonoid isolated from a Chinese traditional medicinal plant, in isolated thoracic aortic rings of mice. The study revealed that scutellarin-induced relaxation of phenylephrine-stimulated contractions was predominantly endothelium-dependent and likely involved the catalase-sensitive nitric oxide synthase signaling pathway. The
Drugs
Researchers have made significant strides in understanding the mechanisms of cancer treatment resistance, particularly in the context of DNA methylation and histone acetylation. A study published in the British Journal of Cancer reveals that combined inhibition of these epigenetic processes can enhance gene re-expression and drug sensitivity in vivo. The
Drugs
Researchers at the University of Paris have developed new ifosfamide analogs, C7, C9-dimethyl-ifosfamide, which exhibit reduced neurotoxicity and nephrotoxicity while maintaining their anticancer activity. These analogs were designed to prevent the formation of chloroacetaldehyde, a known toxic metabolite of ifosfamide. The results of in vitro biotransformation studies and cytotoxicity assays
Drugs
Diuretics are among the most commonly used medications in the United States, employed to treat a variety of conditions, including hypertension, heart failure, renal failure, nephrotic syndrome, and cirrhosis. These medications induce negative fluid and sodium balance by increasing urine flow and sodium excretion. P. Reddy and colleagues from the
Drugs
Scientists in Chongqing, People's Republic of China, conducted a study to evaluate aspirin responsiveness in patients with unstable angina pectoris (UAP) using whole blood aggregometry. The researchers aimed to differentiate aspirin-resistant patients into pharmacokinetic or pharmacodynamic type. They measured platelet aggregation in 70 normal volunteers and 104 UAP
